
COVID-19 is caused by SARS-CoV-2, which originated in Wuhan, Hubei province, Central China, in December 2019 and since then has spread rapidly, resulting in a severe pandemic. The infected patient presents with varying non-specific symptoms requiring an accurate and rapid diagnostic tool to detect SARS-CoV-2. This is followed by effective patient isolation and early treatment initiation ranging from supportive therapy to specific drugs such as corticosteroids, antiviral agents, antibiotics, and the recently introduced convalescent plasma. The development of an efficient vaccine has been an on-going challenge by various nations and research companies. A literature search was conducted in early December 2020 in all the major databases such as Medline/PubMed, Web of Science, Scopus and Google Scholar search engines. The findings are discussed in three main thematic areas namely diagnostic approaches, therapeutic options, and potential vaccines in various phases of development. Therefore, an effective and economical vaccine remains the only retort to combat COVID-19 successfully to save millions of lives during this pandemic. However, there is a great scope for further research in discovering cost-effective and safer therapeutics, vaccines and strategies to ensure equitable access to COVID-19 prevention and treatment services.
Citation: Srikanth Umakanthan, Vijay Kumar Chattu, Anu V Ranade, Debasmita Das, Abhishekh Basavarajegowda, Maryann Bukelo. A rapid review of recent advances in diagnosis, treatment and vaccination for COVID-19[J]. AIMS Public Health, 2021, 8(1): 137-153. doi: 10.3934/publichealth.2021011
[1] | Yicang Zhou, Zhien Ma . Global stability of a class of discrete age-structured SIS models with immigration. Mathematical Biosciences and Engineering, 2009, 6(2): 409-425. doi: 10.3934/mbe.2009.6.409 |
[2] | Dong-Me Li, Bing Chai, Qi Wang . A model of hepatitis B virus with random interference infection rate. Mathematical Biosciences and Engineering, 2021, 18(6): 8257-8297. doi: 10.3934/mbe.2021410 |
[3] | Xichao Duan, Sanling Yuan, Kaifa Wang . Dynamics of a diffusive age-structured HBV model with saturating incidence. Mathematical Biosciences and Engineering, 2016, 13(5): 935-968. doi: 10.3934/mbe.2016024 |
[4] | Tingting Xue, Long Zhang, Xiaolin Fan . Dynamic modeling and analysis of Hepatitis B epidemic with general incidence. Mathematical Biosciences and Engineering, 2023, 20(6): 10883-10908. doi: 10.3934/mbe.2023483 |
[5] | Bao-Zhu Guo, Li-Ming Cai . A note for the global stability of a delay differential equation of hepatitis B virus infection. Mathematical Biosciences and Engineering, 2011, 8(3): 689-694. doi: 10.3934/mbe.2011.8.689 |
[6] | Maysaa Al Qurashi, Saima Rashid, Fahd Jarad . A computational study of a stochastic fractal-fractional hepatitis B virus infection incorporating delayed immune reactions via the exponential decay. Mathematical Biosciences and Engineering, 2022, 19(12): 12950-12980. doi: 10.3934/mbe.2022605 |
[7] | Tahir Khan, Fathalla A. Rihan, Muhammad Ibrahim, Shuo Li, Atif M. Alamri, Salman A. AlQahtani . Modeling different infectious phases of hepatitis B with generalized saturated incidence: An analysis and control. Mathematical Biosciences and Engineering, 2024, 21(4): 5207-5226. doi: 10.3934/mbe.2024230 |
[8] | Jiying Ma, Shasha Ma . Dynamics of a stochastic hepatitis B virus transmission model with media coverage and a case study of China. Mathematical Biosciences and Engineering, 2023, 20(2): 3070-3098. doi: 10.3934/mbe.2023145 |
[9] | C. Connell McCluskey . Global stability for an SEI model of infectious disease with age structure and immigration of infecteds. Mathematical Biosciences and Engineering, 2016, 13(2): 381-400. doi: 10.3934/mbe.2015008 |
[10] | Tailei Zhang, Hui Li, Na Xie, Wenhui Fu, Kai Wang, Xiongjie Ding . Mathematical analysis and simulation of a Hepatitis B model with time delay: A case study for Xinjiang, China. Mathematical Biosciences and Engineering, 2020, 17(2): 1757-1775. doi: 10.3934/mbe.2020092 |
COVID-19 is caused by SARS-CoV-2, which originated in Wuhan, Hubei province, Central China, in December 2019 and since then has spread rapidly, resulting in a severe pandemic. The infected patient presents with varying non-specific symptoms requiring an accurate and rapid diagnostic tool to detect SARS-CoV-2. This is followed by effective patient isolation and early treatment initiation ranging from supportive therapy to specific drugs such as corticosteroids, antiviral agents, antibiotics, and the recently introduced convalescent plasma. The development of an efficient vaccine has been an on-going challenge by various nations and research companies. A literature search was conducted in early December 2020 in all the major databases such as Medline/PubMed, Web of Science, Scopus and Google Scholar search engines. The findings are discussed in three main thematic areas namely diagnostic approaches, therapeutic options, and potential vaccines in various phases of development. Therefore, an effective and economical vaccine remains the only retort to combat COVID-19 successfully to save millions of lives during this pandemic. However, there is a great scope for further research in discovering cost-effective and safer therapeutics, vaccines and strategies to ensure equitable access to COVID-19 prevention and treatment services.
Aeroengine is an important equipment to propel the aircraft forward and its total thrust is the sum of the thrust generated by the core engine and the turbine fan. The air flow state between adjacent blades of the turbine fan determines the thrust value of aeroengine. Since the experiments cost a lot, numerical simulations become an essential part of the blade geometry design and optimization [5,10,2,12,7]. Nevertheless, many difficulties arise in numerical simulation such as nonlinearity, high Reynolds number, complex three-dimensional (3D) geometrical domains, and boundary layer effect (see, e.g., [9]). In order to alleviate these difficulties, we will use the dimension splitting method to simulate the airflow state of aeroengine blade fan.
Based on the article [6], we establish a semi-geodesic coordinate system (called R-coordinate system), whose two basis vectors are on the manifold, and the other is along the hub circle. Thus, Navier-Stokes equations (NSEs) in the R-coordinate system can be rewritten as a set of membrane operator equations on the blade surface, and the bending operator equations along the hub circle [8]. By using Euler central difference scheme to approximate the third variable, the 3D NSEs become a series of two-dimensional (2D) equations with three variables. After successively iterations, the approximate solution to the NSEs can be obtained. Obviously, the significant feature of this new method is this method only solves the 2D problem in each sub-domain. In addition, it can alleviate the boundary layer effect by approaching adjacent surfaces, and the parameterized surface provides convenience for blade design and optimization.
The purpose of this work is to introduce our proposed method to simulate the flow state of the channel of aeroengine turbine fan. A lot of work has been carried out in the field of viscous flow and its applications in aeroengine turbine [16,15,4,11,14,13,3]. In this paper, a toy model is designed to give a comparison between our novel method and traditional methods. It turns out the new method shows a good performance for the toy model. Then we apply the proposed method to simulate the flow state of aeroengine turbine fan.
The present paper is built up as follows. In Section 2, some essential differential geometry knowledge is briefly introduced, then the R-coordinate system is established. Meanwhile, the NSEs' new form, splitting method and the variational form are formulated in Sections 3. Furthermore, we derive the finite element form in Section 4. Section 5 presents the numerical results, which contain the comparison of the new method and traditional methods, and the simulation results of aeroengine turbine fan.
In this section, we establish a new coordinate system according to the geometric shape of the blade and give the relationship between the new coordinate system and the rectangular coordinate system and the cylindrical coordinate system. To express concisely and clearly, we let Greek letters
Compared with the size of the aircraft engine fan, the thickness of the fan blade can be neglected. Thus the blade surface
ℜ(x)=rer+rΘ(r,z)eθ+zk. | (2.1) |
Here
The channel
ℜ(x;ξ)=rer+rθeθ+zk, | (2.2) |
where
Let
x1=z,x2=r,ξ=ε−1(θ−Θ(x)), |
it is clear that the Jacobian matrix
(r,θ,z)→(x1,x2,ξ):x1=z,x2=r,ξ=ε−1(θ−Θ(x)). | (2.3) |
In the R-coordinate system, the fixed region
Since the new coordinate is established, these basis vectors become a bridge to communicate different coordinate systems. Let
{er=cosθi+sinθj,eθ=−sinθi+cosθj,i=cosθer−sinθeθ,j=sinθer+cosθeθ. |
The basis vectors of the R-coordinate system are denoted as
{eα=∂αℜ=∂αxi+∂αyj+∂αzk,α=1,2,e3=∂∂ξ(ℜ)=∂x∂ξi+∂y∂ξj+∂z∂ξk, | (2.4) |
where
{x:=x(x1,x2,ξ)=rcosθ=x2cos(εξ+Θ(x1,x2)),y:=y(x1,x2,ξ)=rsinθ=x2sin(εξ+Θ(x1,x2)),z:=z(x1,x2,ξ)=x1. |
By straightforward calculation, the relationship between base vectors is as follows
{e1=x2Θ1eθ+k=−x2sinθΘ1i+x2cosθΘ1j+k,e2=Θ2x2eθ+er=(cosθ−x2sinθΘ2)i+(sinθ+x2cosθΘ2)j,e3=x2εeθ=−εx2sinθi+εx2cosθj,er=e2−ε−1Θ2e3,eθ=(εx2)−1e3,k=e1−ε−1Θ1e3,i=cosθe2−(ε−1cosθΘ2+(εx2)−1sinθ)e3,j=sinθe2+((εx2)−1cosθ−ε−1Θ2sinθ)e3, | (2.5) |
where
The metric tensor
aαβ:=eαeβ=δαβ+r2ΘαΘβ, |
and it is easy to see that
a=det(aαβ)=1+r2|∇Θ|2>0, | (2.6) |
where
Similarly, the covariant and contravariant components of metric tensor are
gij=eiej,gij=eiej. |
By calculation, they can be expressed as (cf.[5])
{gαβ=aαβ,g3β=gβ3=εr2Θβ,g33=ε2r2,gαβ=δαβ,g3β=gβ3=−ε−1Θβ,g33=(εr)−2a. | (2.7) |
As described in our previous article [6], for given
In this section, we derive the flows state governed by the incompressible rotational NSEs through employing differential operators in the R-coordinate system. Because of the lighter mass of air, its body force is neglected and the rotational NSEs can be expressed as
{∂u∂t−νΔu+(u∇)u+2ω×u+∇p=−ω×(ω×r),divu=0. | (3.1) |
For a time-dependent problem, we usually discretize the problem in time and solve the static problem at each time step, then the time-dependent problem is reduced to a static problem at each time step. If we consider an implicit time discretization (e.g., the backward Euler method) to equation (3.1) with time-step size
{u−νκΔu+κ(u∇)u+2κω×u+κ∇p=−κω×(ω×r)+fu,divu=0, | (3.2) |
where
Assume that
Γijk=ei⋅ejk,∇kui=∂ui∂xk+Γikmum,∗Γαβσ=eα⋅eβλ,∗∇βuα=∂uα∂xβ+∗Γαβσuσ, |
where
Lemma 3.1. [6] By denoting
1). The Laplace operator
Δui=˜Δui+2g3γ∗∇γ∂ui∂ξ+g33∂2ui∂ξ2+Li3γ∂uγ∂ξ+Li33∂u3∂ξ+Liσγ∗∇σuγ+Li0γuγ+δi3L3σ3∗∇σu3, | (3.3) |
where
{Lα3γ=−(εr)−1(Θ2δαγ+2aδ2αΘγ)−˜ΔΘδαγ,L33γ=−2(εr)−2(r2ΘβΘβγ−r−1δ2γ),Lα33=−2rδ2α,L333=−(εr)−1(r˜ΔΘ+Θ2),Lασγ=2rδ2αΘσΘγ−(r|∇Θ|2−r−1)δ2σδαγ,L3σγ=2(εr)−1(δ2σΘγ+rΘγσ)Lα0γ={Θγ[(a+1)Θ2+r˜ΔΘ]−r−2δ2γ+rΘβΘβγ}δ2α,L30γ=(εr)−1(3Θ2γ+2(r2Θ2αΘα+rΘ22)Θγ+)rΘααγ+r−2Θ2δ2γ,L3σ3=(3r−1−r|∇Θ|2)δ2σ, | (3.4) |
and
2). Its related items coriolis force and centrifugal force satisfy, respectively,
C=2κω×u=κCijujei, | (3.5) |
fic=−κεijkωj(→ω×r)k=κεijkgjmωmεklnωlrn=κεijkgjmωmεklnωlgn2r, | (3.6) |
where
3). The pressure gradient is
∇p=[gαβ∂p∂xβ+gα3∂p∂ξg3β∂p∂xβ+g33∂p∂ξ]=[∂p∂xα−ε−1Θα∂p∂ξ−ε−1Θβ∂p∂xβ+(rε)−2a∂p∂ξ]. |
4). The nonlinear term in equation (3.1) is
B(u,u)=κ(u∇)u=κBi(u)ei=κ[uβ∗∇βuα+u3∂uα∂ξ+nαkmukumuβ∗∇βu3+u3∂u3∂ξ+n3kmukum], | (3.7) |
where
{nαλσ=0,nα3β=nαβ3=−rεδ2αΘβ,nα33=−rε2δ2α,n333=rεΘ2,n3λσ=(rε)−1(a2λΘσ+δ2σΘλ)+ε−1Θλσ,n33β=n3β3=r−1a2β. |
5). The mass conservation formula can be rewritten as
div u=∂uα∂xα+∂u3∂ξ+u2r,∗divu=∂uα∂xα−rΘ2Θσuσ. | (3.8) |
By Lemma 3.1, the incompressible rotational NSEs in the R-coordinate system can be rewritten as
{ui+κ{uβ∗∇βui+u3∂ui∂ξ+nikmukum+Cijuj−ν[˜Δui+2g3γ∗∇γ∂ui∂ξ+g33∂2ui∂ξ2+Li3γ∂uγ∂ξ+Li33∂u3∂ξ+Liσγ∗∇σuγ+Li0γuγ+δi3L3σ3∗∇σu3]+giβ∂p∂xβ+gi3∂p∂ξ}=Fi,∂uβ∂xβ+∂u3∂ξ+u2r=0, | (3.9) |
where
Fi=fic+fiu. |
And its channel region and boundaries are
{Ω={(x1,x2,ξ)|(x1,x2)∈D,−1≤ξ≤1,},∂Ω=Γin∪Γout∪ℑ+∪ℑ−∪Γt∪Γb. | (3.10) |
The initial and boundary value conditions are
u|t=0=uo,u|ℑ+∪ℑ−=0,u|Γin=uin. | (3.11) |
In this section, the finite-element-difference method will be presented. The first step is to divide the interval
[−1,+1]=∪N−1k=0[ξk,ξk+1],ξk=−1+kτ,k=0,1,⋯N−1. |
Then the domain
∂w∂ξ≃wk+1−wk−12τ,∂2w∂ξ2≃wk+1−2wk+wk−1τ2. | (3.12) |
where
[w]+k:=wk+1+wk−1τ2,[w]−k:=wk+1−wk−12τ. | (3.13) |
Plugging (3.13) into (3.9), we obtain
{ui+κ{uβ∗∇βui+u3[ui]−k+nikmukum−ν[˜Δui+2g3γ∗∇γ[ui]−k+g33([ui]+k−2uiτ2)+Li3γ[uγ]−k+Li33[u3]−k+Liσγ∗∇σuγ+Li0γuγ+δi3L3σ3∗∇σu3]+giβ∂p∂xβ+gi3[p]−k+Cijuj}=˜Fik,∂uα∂xα+[u3]−k+u2r=0, | (3.14) |
where
˜Fik:=1τ∫ξk+1ξkFi. | (3.15) |
And its boundary conditions are
uk|γ0=0,uk|γin=uin,∂D=γ0∪γin∪γout, | (3.16) |
where
Introduce the Hilbert space
V(D)={u∈H1(D)×H1(D)×H1(D),u=0|γ0∪γin}, |
then its inner product and norms are given, respectively, by
(w,v)D=∫Ωaijwivj√adx,aij={aαβ=aαβ,aα3=a3α=0,a33=1},|w|21,D=∑α∑j‖∂αwj‖20,D,‖w‖20,D=∑j‖wj‖20,D,‖w‖21,D=|w|21,D+‖w‖20,D. |
Without the ambiguity, the index `D' is often omitted.
For clarity and simplicity, we denote
{Li(k):=−κν(˜Δuik+Liσγ∗∇σuγk+Li0γuγk−2g33τ−2uik+δi3L3σ3∗∇σu3k)+uik,Bi(k):=κ(uβk∗∇βuik+nilmulkumk),Ci(k):=κCimumk,Si:=−κν(2g3γ∗∇γ[ui]−k+g33[ui]+k+Li3γ[uγ]−k+Li33[u3]−k)+κu3k[ui]−k,Pi:=κgi3[p]−k. | (3.17) |
Meanwhile, we denote
{Lα(k)+Bα(k)+Cα(k)+κgαβ∂pk∂xβ=ˆFαk,L3(k)+B3(k)+C3(k)+κg3β∂pk∂xβ=ˆF3k,∂uα∂xα+[u3]−k+u2r=0. | (3.18) |
Thus, the variational problem corresponding to the boundary value problem of the NSEs is as follows:
{Seek uk∈L∞(0,T;V(D))+uin, pk∈L2(D),k=0,1,2,⋯,N−1,s.t.a(uk,v)+(C(uk),v)+(L(uk),v)+b(uk,uk,v)−(pk,m(v))=(ˆFk,v)−<h,v>γout,∀v∈V(D),(∂uαk∂xα+u2kr,q)=([u3]−k,q),∀q∈L2(D), | (3.19) |
where the linear, bilinear and trilinear forms are given, respectively,
{a(uk,v)=νκ(aij∂λuik,∂λvj)+νκ(ˆaijuik,vj)+(aijui,vj),ˆaij=aijr−2aα2τ,(C(uk),v)=κ(C∗i,vi),C∗β=aαβCαmumk,C∗3=C3mumk,(L(uk),v)=νκ(L∗i,vi),L∗β=∂λaαβ∂λuαk−aαβ(Lασν∗∇σuνk+Lα0νuνk),L∗3=−(L3σλ∗∇σuλk+L3σ3∗∇σu3k+L30σuσk),b(uk,uk,v)=(κaijBi(k),vj),(ˆFk,v)=(aijˆFik,vj),<h,v>γout=−∫γoutκμaij∂λuikvjnλdl+∫γoutκpk(aαλvα−εΘβv3)nλdl,m(v)=κ(∂αvα−εΘβ∂βv3−ε˜ΔΘv3). | (3.20) |
In this section, we apply the Taylor-Hood elements, i.e.,
Vh:={vh∈C0(ˉΩ);vh|K∈P2(K),∀K∈Th},Mh:={ph∈C0(ˉΩ);ph|K∈P1(K),∀K∈Th}. | (4.1) |
The product space
{Seek wh∈Vh, ph∈Mh s.t.a(wh,vh)+(C(wh),vh)+(L(wh),vh)+b(wh,wh,vh)−(ph,m(vh))=(ˆFk,vh)−<h,vh>γout,∀vh∈Vh,(∂wαh∂xα+w2hr,qh)=−([w3h]−k,qh),∀qh∈Mh. | (4.2) |
Suppose the finite element basis functions are denoted as
φi(x),i=1,2,⋯,NG1, ϕi(x), i=1,2,⋯NG2, |
where
wmh=NG1∑i=1Ximφi(x),ph=NG2∑i=1Piϕi(x),m=1,2,3,vkh=NG1∑i=1Yikφi(x),qh=NG2∑i=1Qiϕi(x),k=1,2,3. | (4.3) |
Assume solution vector
Wm={X1m,X2m,⋯XNG1m}T,W={W1,W2,W3}T,Vk={Y1k,Y2k,⋯YNG1k}T,V={V1,V2,V3}T,P={P1,⋯,PNG2}T,Q={Q1,⋯,QNG2}T. | (4.4) |
Substitute (4.4) into (4.2), we obtain the result on 2D membrane operator:
{a(wh,vh)=KαβijXiαYjβ,(L(wh),vh)=LτβijXiτYjβ,(C(wh,ω),vh)=CτβijXiτYjβ+C3βijXi3Yjβ,A0(wh,vh)=a(wh,vh)+(L(wh),vh)+(C(wh,ω),vh)=[KτβijXiτ+K3βijXi3]Yjβ,b(wh,wh,vh)=blm,βik,jXilXkmYjβ,(ph,m(vh))=B∗βijPiYjβ | (4.5) |
where
{Kαβij=κν[(aαβ∂λφi,∂λφj)+α2τ(aαβar−1φi,r−1φj)]+(aαβφi,φj),Lτβij=κν(∂λaαβ∂λφiδατ,φj)−κνaαβ((Lασν∂σδντ+LασνΓνσλδλτ+Lα0νδντ)φi,φj),Cτβij=(κaαβCατφi,φj),C3βij=(κaαβCα3φi,φj),Kτβij=Kαβijδτα+Lτβij+Cτβij,K3βij=C3βij,blm,βik,j=κ(aαβ{δlλφi[∂λφkδαm+Γαλσφkδσm]+nαlmφiφk},φj),B∗βij=κ(ϕi,∂βφj). |
Proof. In this proof, we only prove
∗∇σwν=∂σwν+Γνσλwλ,∗∇σw3=∂σw3, |
we obtain
(L(wh),vh)=κ(−νaαβLασν∗∇σwνh−νaαβLα0νwνh,vβh)+κ(ν∂λaαβ∂λwαh,vβh)=κ(−νaαβLασν[∂σwνh+Γνσλwλh]−νaαβLα0νwνh,vβh)+κ(ν∂λaαβ∂λwαh,vβh)=κν(∂λaαβ∂λwαh−aαβLασν∂σwνh,vβh)−κν(aαβLασνΓνσλwλh+aαβLα0νwνh,vβh)=κν(∂λaαβ∂λφiδατ−aαβLασν∂σφiδντ,φj)XiτYjβ−κν(aαβLασνΓνσλφiδλτ+aαβLα0νφiδντ,,φj)XiτYjβ=LτβijXiτYjβ. |
The remainder of the argument is analogous and is left to the reader.
Next, we will give the discrete scheme on the right side of the formula (4.2). According to the definition of inner product in space
{(ˆFk,v)=(aαβˆFαk,vβ)=ˆFβjYjβ,<h,v>γout=∫−κνaαβ∂λφiXiαφjYjβnλdl+∫κaαβϕiPiφjYjαnβdl=ˆHβjYjβ. |
Thus, we obtain
KτβijXiτ+K3βijXi3+blm,βik,jXilXkm−B∗βijPi=Fβj, | (4.6) |
where
{a(w3h,v3h)=K33ijXi3Yj3,(L(w3h),v3h)=Lτ3ijXiτYj3+L33ijXi3Yj3,(C(w3h,ω),v3h)=C3αijXiαYj3+C33ijXi3Yj3,A0(w3h,v3h)=[Kα3ijXiα+K33ijXi3]Yj3,b(w3,w3,v3)=blm,3ik,jXilXkmYj3,(ph,m(vh))=B∗3ijPiYj3, | (4.7) |
where
{K33ij=κν(∂λφi,∂λφj)+κνα2τ(ar−1φi,r−1φj)+(φi,φj),Lτ3ij=−(κν[L3σλ(∂σφiδλτ+Γλστφi)+L30τφi],φj),L33ij=−(κνL3σ3∂σφi,φj),Cα3ij=(κC3αφi,φj),C33ij=(κC33φi,φj),K33ij=K33ij+L33ij+C33ij,Kα3ij=Lα3ij+Cα3ij,blm,3ik,j=κ(φiδβlδ3m∂βφk+n3lmφiφk,φj),B∗3ij=−κ(ϕi,εΘβ∂βφj+ε˜ΔΘφj). |
And its right terms are
{(ˆF3k,v3)=(ˆF3k,Yj3φj)=ˆF3jYj3,<h3,v3>γout=−∫κν∂λφiXi3φjYj3nλdl−∫κεΘβϕiPiφjYj3nλdl=ˆH3jYj3. |
It is easy to verify it, so its proof will not be given here. Then the bending operators becomes
Kα3ijXiα+K33ijXi3+bml,3ik,jXimXkl−B∗3ijPi=F3j, | (4.8) |
where
Finally, we obtain the finite element algebraic equations of equation (3.19), i.e.,
{KτβijXiτ+K3βijXi3+blm,βik,jXilXkm−B∗βijPi=Fβj,Kα3ijXiα+K33ijXi3+bml,3ik,jXimXkl−B∗3ijPi=F3j,MijXiα=−(φi[Xi3]−k,ϕj), | (4.9) |
where
Mα∗ij=(∂αφi+r−1φiδα2). |
In this section, for certain examples, the results of the new algorithm program and the traditional algorithm program will be compared to verify the accuracy of the new algorithm program. And the new algorithm program shows good performance. Then, based on the new algorithm, the flow state of the gas in the fan channel of an aeroengine is given.
In this part, a simple model is provided to give the comparison between results obtained by the dimension splitting method (DS method) and traditional 3D method (T3D method). In this example, we adopt stationary model and assume
51 2D-manifolds and 4987 elements per surface are used to partition the channel and for DS method while 254867 elements are used for T3D method. In this model, we assume
As mentioned above, the flow state determines the maximum thrust that aeroengine turbine fan can provide. Our main purpose is using the DS method to simulate the flow state of the aeroengine turbine fan. In addition to the alleviation of boundary layer effects and make parallelism easier, DS method can give one clear design objective
In this article, we adopt the blades provided by the partner airlines which shape can be shown in Figure 15. Its meshes in the R-coordinate system are shown in Figure 1, and 51 2D-manifolds are used in this case. The velocity at inlet is 80 m/s and the rotating angular velocity is 80 rad/s. Figure 11 – Figure 12 show the pressure distribution on the blade surface. Because of the rotation, positive pressure surface and negative pressure surface have different pressure distribution. The pressure distribution of the positive pressure surface is higher than that of the negative pressure surface. Because the blade is cocked up at the bottom (see Figure 15), the pressure distribution near the bottom of the blade is obviously different from other places. Through formula transformation, we present the 3D model of blade pressure and velocity in Figure 13 – Figure 14.
Meanwhile, we show the velocity distribution at outlet in Figure 16. The velocity on the outside is significantly higher than that on the inside, and the velocity in the middle of the channel is also higher than that near the blade, which is consistent with common sense. From Figure 16, we can find that the maximum velocity is located at the edge of the blade, which can reach 130 m/s.
In this work, we conduct numerical simulations for 3D flow in the flow channel of the aeroengine turbine fan based on the dimension splitting method. However, the simulation of the flow states between the blades is not the ultimate goal. Our ultimate goal is to use the simulation results to design or optimize the blades. Meanwhile, the parameterized blade surface provides convenience for blade design and optimization. Thus, it will be the focus of follow-up research to optimize the blade by combining the inverse problem. In addition, compressible flow and boundary layer phenomenons are also the focus of the follow-up research.
The work of G. Ju was partially supported by the NSF of China (No. 11731006), the Shenzhen Sci-Tech Fund (No. JCYJ20170818153840322), and Guangdong Provincial Key Laboratory of Computational Science and Material Design No. 2019B030301001. The work of R. Chen was supported by the NSF of China (No. 61531166003) and Shenzhen Sci-Tech fund (No. JSGG20170824154458183 and ZDSYS201703031711426). The work of J. Li was partially supported by the NSF of China (No. 11971221) and Shenzhen Sci-Tech fund (No. JCYJ20190809150413261). The work of K. Li was supported by the NSF of China under the grant No. 10971165 and 10771167.
[1] |
Pooladanda V, Thatikonda S, Godugu C (2020) The current understanding and potential therapeutic options to combat COVID-19. Life Sci 254: 117765. doi: 10.1016/j.lfs.2020.117765
![]() |
[2] |
Wang H, Li X, Li T, et al. (2020) The genetic sequence, origin, and diagnosis of SARS-CoV-2. Eur J Clin Microbiol Infect Dis 39: 1629-1635. doi: 10.1007/s10096-020-03899-4
![]() |
[3] |
Li H, Liu SM, Yu XH, et al. (2020) Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents 55: 105951. doi: 10.1016/j.ijantimicag.2020.105951
![]() |
[4] | Wu J, Deng W, Li S, et al. (2020) Advances in research on ACE2 as a receptor for 2019-nCoV. Cell Mol Life Sci 1-14. |
[5] | Umakanthan S, Sahu P, Ranade AV, et al. (2020) Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Postgrad Med J 96: 753-758. |
[6] |
Fu L, Wang B, Yuan T, et al. (2020) Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. J Infect 80: 656-665. doi: 10.1016/j.jinf.2020.03.041
![]() |
[7] |
Iyer M, Jayaramayya K, Subramaniam MD, et al. (2020) COVID-19: an update on diagnostic and therapeutic approaches. BMB Rep 53: 191-205. doi: 10.5483/BMBRep.2020.53.4.080
![]() |
[8] |
Touma M (2020) COVID-19: molecular diagnostics overview. J Mol Med (Berl) 98: 947-954. doi: 10.1007/s00109-020-01931-w
![]() |
[9] |
Huang C, Wang Y, Li X, et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395: 497-506. doi: 10.1016/S0140-6736(20)30183-5
![]() |
[10] |
Zhou F, Yu T, Du R, et al. (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395: 1054-1062. doi: 10.1016/S0140-6736(20)30566-3
![]() |
[11] | Zheng F, Tang W, Li H, et al. (2020) Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. Eur Rev Med Pharmacol Sci 24: 3404-3410. |
[12] |
Chu DKW, Pan Y, Cheng SMS, et al. (2020) Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia. Clin Chem 66: 549-555. doi: 10.1093/clinchem/hvaa029
![]() |
[13] |
Loeffelholz MJ, Tang YW (2020) Laboratory diagnosis of emerging human coronavirus infections—the state of the art. Emerg Microbes Infect 9: 747-756. doi: 10.1080/22221751.2020.1745095
![]() |
[14] |
Emery SL, Erdman DD, Bowen MD, et al. (2004) Real-time reverse transcription-polymerase chain reaction assay for SARS-associated Coronavirus. Emerg Infect Dis 10: 311-316. doi: 10.3201/eid1002.030759
![]() |
[15] |
Wölfel R, Corman VM, Guggemos W, et al. (2020) Virological assessment of hospitalized patients with COVID-2019. Nature 581: 465-469. doi: 10.1038/s41586-020-2196-x
![]() |
[16] |
Hans R, Marwaha N (2014) Nucleic acid testing-benefits and constraints. Asian J Transfus Sci 8: 2-3. doi: 10.4103/0973-6247.126679
![]() |
[17] | La Marca A, Capuzzo M, Paglia T, et al. (2020) Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays. Reprod Biomed Online . |
[18] | Doi A, Iwata K, Kuroda H, et al. (2020) Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study. medRxiv . |
[19] | Li Z, Yi Y, Luo X, et al. (2020) Development and Clinical Application of A Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis. J Med Virol 27: 25727. |
[20] | Liu R, Liu X, Han H, et al. The comparative superiority of IgM-IgG antibody test to real-time reverse transcriptase PCR detection for SARS-CoV-2 infection diagnosis 2020 (2020) .Available from: https://doi.org/10.1101/2020.03.28.20045765. |
[21] |
Grant BD, Anderson CE, Williford JR, et al. (2020) SARS-CoV-2 Coronavirus Nucleocapsid Antigen-Detecting Half-Strip Lateral Flow Assay Toward the Development of Point of Care Tests Using Commercially Available Reagents. Anal Chem 92: 11305-11309. doi: 10.1021/acs.analchem.0c01975
![]() |
[22] |
Burki TK (2020) Testing for COVID-19. Lancet Respir Med 8: e63-e64. doi: 10.1016/S2213-2600(20)30247-2
![]() |
[23] | Chen H, Ai L, Lu H, et al. (2020) Clinical and imaging features of COVID-19. Radiol Infect Dis . |
[24] |
Singh AK, Majumdar S, Singh R, et al. (2020) Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician's perspective. Diabetes Metab Syndr 14: 971-978. doi: 10.1016/j.dsx.2020.06.054
![]() |
[25] |
Perez A, Jansen-Chaparro S, Saigi I, et al. (2014) Glucocorticoid-induced hyperglycemia. J Diabetes 6: 9-20. doi: 10.1111/1753-0407.12090
![]() |
[26] |
Singh AK, Singh A, Singh R, et al. (2020) Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies. Diabetes Metab Syndr 14: 641-648. doi: 10.1016/j.dsx.2020.05.018
![]() |
[27] |
Bhatraju PK, Ghassemieh BJ, Nichols M, et al. (2020) Covid-19 in Critically Ill Patients in the Seattle Region—Case Series. N Engl J Med 382: 2012-2022. doi: 10.1056/NEJMoa2004500
![]() |
[28] |
Singh AK, Singh A, Shaikh A, et al. (2020) Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr 14: 241-246. doi: 10.1016/j.dsx.2020.03.011
![]() |
[29] |
Moore N (2020) Chloroquine for COVID-19 Infection. Drug Saf 43: 393-394. doi: 10.1007/s40264-020-00933-4
![]() |
[30] | Owa AB, Owa OT (2020) Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial? J Microbiol Immunol Infect . |
[31] |
Uzunova K, Filipova E, Pavlova V, et al. (2020) Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. Biomed Pharmacother 131: 110668. doi: 10.1016/j.biopha.2020.110668
![]() |
[32] | Heidary F, Gharebaghi R, et al. (2020) Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot (Tokyo) 1-10. |
[33] | Gupta D, Sahoo AK, Singh A (2020) Ivermectin: potential candidate for the treatment of Covid 19. Braz J Infect Dis . |
[34] |
Coomes EA, Haghbayan H (2020) Favipiravir, an antiviral for COVID-19? J Antimicrob Chemother 75: 2013-2014. doi: 10.1093/jac/dkaa171
![]() |
[35] | Cai Q, Yang M, Liu D, et al. (2020) Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing) . |
[36] | Wu R, Wang L, Kuo HD, et al. (2020) An Update on Current Therapeutic Drugs Treating COVID-19. Curr Pharmacol Rep 1-15. |
[37] |
Huttner BD, Catho G, Pano-Pardo JR, et al. (2020) COVID-19: don't neglect anti-microbial stewardship principles!. Clin Microbiol Infect 26: 808-810. doi: 10.1016/j.cmi.2020.04.024
![]() |
[38] |
Rawson TM, Ming D, Ahmad R, et al. (2020) Anti-microbial use, drug-resistant infections and COVID-19. Nat Rev Microbiol 18: 409-410. doi: 10.1038/s41579-020-0395-y
![]() |
[39] | Cai X, Ren M, Chen F, et al. (2020) Blood transfusion during the COVID-19 outbreak. Blood Transfus 18: 79-82. |
[40] | Kumar S, Sharma V, Priya K (2020) Battle against COVID-19: Efficacy of Convalescent Plasma as an emergency therapy. Am J Emerg Med . |
[41] |
Mair-Jenkins J, Saavedra-Campos M, Baillie JK (2015) The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 211: 80-90. doi: 10.1093/infdis/jiu396
![]() |
[42] | Valk SJ, Piechotta V, Chai KL, et al. (2020) Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Cochrane Db Syst Rev 5: CD013600. |
[43] | Hartman WR, Hess AS, Connor JP Hospitalized COVID-19 Patients treated with Convalescent Plasma in a Mid-size City in the Midwest (2020) .Available from: https://www.researchgate.net/publication/346772157_Hospitalized_COVID-19_Patients_treated_with_Convalescent_Plasma_in_a_Mid-size_City_in_the_Midwest. |
[44] |
Li L, Zhang W, Hu Y, et al. (2020) Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA 324: 460-470. doi: 10.1001/jama.2020.10044
![]() |
[45] |
Rajarshi K, Chatterjee A, Ray S (2020) Combating COVID-19 with Mesenchymal Stem Cell therapy. Biotechnol Rep (Amst) 26: e00467. doi: 10.1016/j.btre.2020.e00467
![]() |
[46] |
Golchin A, Seyedjafari E, Ardeshirylajimi A (2020) Mesenchymal Stem Cell Therapy for COVID-19: Present or Future. Stem Cell Rev Rep 16: 427-433. doi: 10.1007/s12015-020-09973-w
![]() |
[47] |
Golchin A, Farahany TZ, Khojasteh A, et al. (2018) The clinical trials of Mesenchymal stem cell therapy in skin diseases: An update and concise review. Curr Stem Cell Res Ther 14: 22-33. doi: 10.2174/1574888X13666180913123424
![]() |
[48] | Kewan T, Covut F, Al-Jaghbeer MJ, et al. (2020) Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study. E Clin Med 100418. |
[49] | Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. (2020) Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol 2. |
[50] | Cantini F, Niccoli L, Nannini C, et al. (2020) Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. J Infect . |
[51] |
Cantini F, Niccoli L, Matarrese D, et al. (2020) Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect 81: 318-356. doi: 10.1016/j.jinf.2020.04.017
![]() |
[52] |
Maoujoud O, Asserraji M, Ahid S, et al. (2020) Anakinra for patients with COVID-19. Lancet Rheumatol 2: e383. doi: 10.1016/S2665-9913(20)30177-6
![]() |
[53] |
Filocamo G, Mangioni D, Tagliabue P, et al. (2020) Use of anakinra in severe COVID-19: A case report. Int J Infect Dis 96: 607-609. doi: 10.1016/j.ijid.2020.05.026
![]() |
[54] | Kow CS, Hasan SS (2020) Use of low-molecular-weight heparin in COVID-19 patients. J Vasc Surg Venous Lymphat Disord . |
[55] | Costanzo L, Palumbo FP, Ardita G, et al. (2020) Coagulopathy, thromboembolic complications, and the use of heparin in COVID-19 pneumonia. J Vasc Surg Venous Lymphat Disord . |
[56] | Turshudzhyan A (2020) Anticoagulation Options for Coronavirus Disease 2019 (COVID-19)-Induced Coagulopathy. Cureus 12: e8150. |
[57] |
Boretti A, Banik BK (2020) Intravenous Vitamin C for reduction of cytokines storm in Acute Respiratory Distress Syndrome. PharmaNutrition 12: 100190. doi: 10.1016/j.phanu.2020.100190
![]() |
[58] |
Simonson W (2020) Vitamin C and Coronavirus. Geriatr Nurs 41: 331-332. doi: 10.1016/j.gerinurse.2020.05.002
![]() |
[59] |
Hemilä H (2003) Vitamin C and SARS coronavirus. J Antimicrob Chemother 52: 1049-1050. doi: 10.1093/jac/dkh002
![]() |
[60] | World Health Organization Draft landscape of COVID-19 candidate vaccines (2020) .Available from: https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines. |
[61] |
Day M (2020) Covid-19: four fifths of cases are asymptomatic, China figures indicate. BMJ 369: 1375. doi: 10.1136/bmj.m1375
![]() |
[62] |
Sutton D, Fuchs K, D'Alton M, et al. (2020) Universal Screening for SARS-CoV-2 in Women Admitted for Delivery. N Engl J Med 382: 2163-2164. doi: 10.1056/NEJMc2009316
![]() |
[63] |
Mizumoto K, Kagaya K, Zarebski A, et al. (2020) Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill 25: 2000180. doi: 10.2807/1560-7917.ES.2020.25.10.2000180
![]() |
[64] |
Wrapp D, Wang N, Corbett KS, et al. (2020) Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367: 1260-1263. doi: 10.1126/science.abb2507
![]() |
[65] |
Andersen KG, Rambaut A, Lipkin WI, et al. (2020) The proximal origin of SARS-CoV-2. Nat Med 26: 450-452. doi: 10.1038/s41591-020-0820-9
![]() |
[66] |
Benvenuto D, Giovanetti M, Ciccozzi A, et al. (2020) The 2019-new coronavirus epidemic: Evidence for virus evolution. J Med Virol 92: 455-459. doi: 10.1002/jmv.25688
![]() |
[67] |
Yan R, Zhang Y, Li Y, et al. (2020) Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367: 1444-1448. doi: 10.1126/science.abb2762
![]() |
[68] |
Enjuanes L, Zuñiga S, Castaño-Rodriguez C, et al. (2016) Molecular Basis of Coronavirus Virulence and Vaccine Development. Adv Virus Res 96: 245-286. doi: 10.1016/bs.aivir.2016.08.003
![]() |
[69] |
Song Z, Xu Y, Bao L, et al. (2019) From SARS to MERS, Thrusting Coronaviruses into the Spotlight. Viruses 11: 59. doi: 10.3390/v11010059
![]() |
[70] | Wu F, Wang A, Liu M, et al. (2020) Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv . |
[71] |
Thi Nhu Thao T, Labroussaa F, Ebert N, et al. (2020) Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform. Nature 582: 561-565. doi: 10.1038/s41586-020-2294-9
![]() |
[72] |
Xie X, Muruato A, Lokugamage KG, et al. (2020) An Infectious cDNA Clone of SARS-CoV-2. Cell Host Microbe 27: 841-848. doi: 10.1016/j.chom.2020.04.004
![]() |
[73] |
Dicks MD, Spencer AJ, Edwards NJ, et al. (2012) A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One 7: e40385. doi: 10.1371/journal.pone.0040385
![]() |
[74] |
Fausther-Bovendo H, Kobinger GP (2014) Pre-existing immunity against Advectors. Hum Vaccines Immunother 10: 2875-2884. doi: 10.4161/hv.29594
![]() |
[75] |
Alberer M, Gnad-Vogt U, Hong HS, et al. (2017) Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomized, prospective, first-in-human phase 1 clinical trial. Lancet 390: 1511-1520. doi: 10.1016/S0140-6736(17)31665-3
![]() |
[76] |
Smith TRF, Patel A, Ramos S, et al. (2020) Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun 11: 2601. doi: 10.1038/s41467-020-16505-0
![]() |
[77] | BIONTECH BioNTech and Pfizer announce regulatory approval from German authority Paul-Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine candidates (2020) .Available from: https://investors.biontech.de/node/7431/pdf. |
[78] |
Takashima Y, Osaki M, Ishimaru Y, et al. (2011) Artificial molecular clamp: A novel device for synthetic polymerases. Angew Chem Int Ed 50: 7524-7528. doi: 10.1002/anie.201102834
![]() |
[79] |
Singh K, Mehta S (2016) The clinical development process for a novel preventive vaccine: An overview. J Postgrad Med 62: 4-11. doi: 10.4103/0022-3859.173187
![]() |
[80] |
Wang Q, Zhang L, Kuwahara K, et al. (2016) Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates. ACS Infect Dis 2: 361-376. doi: 10.1021/acsinfecdis.6b00006
![]() |
[81] | de Sousa E, Ligeiro D, Lérias JR, et al. (2020) Mortality in COVID-19 disease patients: Correlating Association of Major histocompatibility complex (MHC) with severe acute respiratory syndrome 2 (SARS-CoV-2) variants. Int J Infect Dis . |
[82] |
Li H, Liu SM, Yu XH, et al. (2020) Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents 55: 105951. doi: 10.1016/j.ijantimicag.2020.105951
![]() |
[83] |
Deb B, Shah H, Goel S (2020) Current global vaccine and drug efforts against COVID-19: Pros and cons of bypassing animal trials. J Biosci 45: 82. doi: 10.1007/s12038-020-00053-2
![]() |
[84] |
Abd El-Aziz TM, Stockand JD (2020) Recent progress and challenges in drug development against COVID-19 Coronavirus (SARS-CoV-2)—an update on the status. Infect Genet Evol 83: 104327. doi: 10.1016/j.meegid.2020.104327
![]() |
[85] |
Polack FP, Thomas SJ, Kitchin N, et al. (2020) C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 383: 2603-2615. doi: 10.1056/NEJMoa2034577
![]() |
[86] |
Walsh EE, Frenck RW, Falsey AR, et al. (2020) Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med 383: 2439-2450. doi: 10.1056/NEJMoa2027906
![]() |
[87] |
Anderson EJ, Rouphael NG, Widge AT, et al. (2020) mRNA-1273 Study Group. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med 383: 2427-2438. doi: 10.1056/NEJMoa2028436
![]() |
[88] |
Giamarellos-Bourboulis EJ, Tsilika M, Moorlag S, et al. (2020) Activate: Randomized Clinical Trial of BCG Vaccination against Infection in the Elderly. Cell 183: 315-323. doi: 10.1016/j.cell.2020.08.051
![]() |
[89] |
Junqueira-Kipnis AP, Dos Anjos LRB, Barbosa LCS, et al. (2020) BCG revaccination of health workers in Brazil to improve innate immune responses against COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials 21: 881. doi: 10.1186/s13063-020-04822-0
![]() |
[90] | Rivas MN, Ebinger JE, Wu M, et al. (2021) BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of health care workers. J Clin Invest 2021 131. |
1. | Jean Pierre II Kouenkam, Joseph Mbang, Yves Emvudu, Global dynamics of a model of hepatitis B virus infection in a sub-Saharan African rural area, 2020, 13, 1793-5245, 2050054, 10.1142/S1793524520500540 | |
2. | Getachew Teshome Tilahun, Woldegebriel Assefa Woldegerima, Nesredin Mohammed, A fractional order model for the transmission dynamics of hepatitis B virus with two-age structure in the presence of vaccination, 2021, 28, 2576-5299, 87, 10.1080/25765299.2021.1896423 | |
3. | Chao Liu, Peng Chen, Qiyu Jia, Lora Cheung, Effects of Media Coverage on Global Stability Analysis and Optimal Control of an Age-Structured Epidemic Model with Multi-Staged Progression, 2022, 10, 2227-7390, 2712, 10.3390/math10152712 | |
4. | Jianquan Li, Yuming Chen, Peijun Zhang, Dian Zhang, Global Stability of a Viral Infection Model with Defectively Infected Cells and Latent Age, 2024, 45, 0252-9599, 555, 10.1007/s11401-024-0028-2 | |
5. | Salah Boulaaras, Aasim Ullah Jan, Tahir Hassan, Taha Radwan, Mathematical modeling and computational analysis of hepatitis B virus transmission using the higher-order Galerkin scheme, 2024, 13, 2192-8029, 10.1515/nleng-2024-0048 |